Sana biotechnology highlights hypoimmune allogeneic car t cell programs and in vivo technology platform with six presentations at 2022 ash annual meeting

Transplanted hypoimmune (hip)-modified allogeneic cd19-targeted car t cells control cd19+ tumor cells in fully immunocompetent allogeneic humanized mice, evading both the adaptive and innate immune systems

SANA Ratings Summary

SANA Quant Ranking